EXEL
Exelixis Breaks Out in 2024 with Strong Momentum in Oncology Business
Exelixis has made significant strides in establishing itself as a multi-compound, multi-franchise oncology business. According to recent conference call transcript from February 25, the company achieved notable growth and momentum in its cabozantinib (cabo) franchise, both in terms of absolute revenue and relative growth compared to competition. In the fourth